The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy
Open accessAbstract
BACKGROUND: The National Lung Screening Trial showed that lung cancer (LC) screening by three annual rounds of low-dose computed tomography (LDCT) reduces LC mortality. We evaluated the benefit of prolonged LDCT screening beyond 5 years, and its impact on overall and LC specific mortality at 10 years. DESIGN: The Multicentric Italian Lung Detection (MILD) trial prospectively randomized 4099 participants, to a screening arm (n = 2376), with further randomization to annual (n = 1190) or biennial (n = 1186) LDCT for a median period of 6 years, or control arm (n = 1723) without intervention. Between 2005 and 2018, 39 293 person-years of follow-up were accumulated. The primary outcomes were 10-year overall and LC specific mortality. Landmark analysis was used to test the long-term effect of LC screening, beyond 5 years by exclusion of LCs and deaths that occurred in the first 5 years. RESULTS: The LDCT arm showed a 39% reduced risk of LC mortality at 10 years [hazard ratio (HR) 0.61; 95% confidence interval (CI) 0.39-0.95], compared with control arm, and a 20% reduction of overall mortality (HR 0.80; 95% CI 0.62-1.03). LDCT benefit improved beyond the 5th year of screening, with a 58% reduced risk of LC mortality (HR 0.42; 95% CI 0.22-0.79), and 32% reduction of overall mortality (HR 0.68; 95% CI 0.49-0.94). CONCLUSIONS: The MILD trial provides additional evidence that prolonged screening beyond 5 years can enhance the benefit of early detection and achieve a greater overall and LC mortality reduction compared with NLST trial. CLINICALTRIALS.GOV IDENTIFIER: NCT02837809.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
Analysis of survival by tumor response.
Anderson, J. R., Cain, K. C., & Gelber, R. D. (1983) · Journal of Clinical Oncology · doi:10.1200/jco.1983.1.11.710 · Cited by 1,107
Analysis of survival by tumor response.
Anderson, J. R., & Davis, R. B. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.1.115 · Cited by 1,000
Overdiagnosis in Low-Dose Computed Tomography Screening for Lung Cancer
Patz, E. F., Pinsky, P., Gatsonis, C., Sicks, J. D., Kramer, B. S., Tammemägi, M. C., Chiles, C., Black, W. C., & Aberle, D. R. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.12738 · Cited by 776
Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges
Seijo, L. M., Peled, N., Ajona, D., Boeri, M., Field, J. K., Sozzi, G., Pio, R., Zulueta, J. J., Spira, A., Massion, P. P., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.023 · Cited by 539
Self-citationPastorino, U., Bellomi, M., Landoni, C., De Fiori, E., Arnaldi, P., Picchio, M., Pelosi, G., Boyle, P., & Fazio, F. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14188-8 · Cited by 452
Self-citationSozzi, G., Boeri, M., Rossi, M., Verri, C., Suatoni, P., Bravi, F., Roz, L., Conte, D., Grassi, M., Sverzellati, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.4357 · Cited by 436
Self-citationPastorino, U., Rossi, M., Rosato, V., Marchianò, A., Sverzellati, N., Morosi, C., Fabbri, A., Galeone, C., Negri, E., Sozzi, G., et al. (2012) · European Journal of Cancer Prevention · doi:10.1097/cej.0b013e328351e1b6 · Cited by 414
Self-citationInfante, M., Cavuto, S., Lutman, F. R., Passera, E., Chiarenza, M., Chiesa, G., Brambilla, G., Angeli, E., Aranzulla, G., Chiti, A., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201408-1475oc · Cited by 365
Results of the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk Profiling
Wille, M. M. W., Dirksen, A., Ashraf, H., Saghir, Z., Bach, K. S., Brodersen, J., Clementsen, P. F., Hansen, H., Larsen, K. R., Mortensen, J., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201505-1040oc · Cited by 341
Field, J. K., Duffy, S. W., Baldwin, D. R., Whynes, D. K., Devaraj, A., Brain, K. E., Eisen, T., Gosney, J., Green, B. A., Holemans, J. A., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207140 · Cited by 337
Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial
Paci, E., Puliti, D., Lopes Pegna, A., Carrozzi, L., Picozzi, G., Falaschi, F., Pistelli, F., Aquilini, F., Ocello, C., Zappa, M., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-209825 · Cited by 311
Yousaf-Khan, U., van der Aalst, C., de Jong, P. A., Heuvelmans, M., Scholten, E., Lammers, J.-W., van Ooijen, P., Nackaerts, K., Weenink, C., Groen, H., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-208655 · Cited by 263
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Lung Cancer Screening
Wood, D. E. (2015) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2014.12.003 · Cited by 255
Patz, E. F., Greco, E., Gatsonis, C., Pinsky, P., Kramer, B. S., & Aberle, D. R. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00621-x · Cited by 184
Becker, N., Motsch, E., Gross, M.-L., Eigentopf, A., Heußel, C. P., Dienemann, H., Schnabel, P. A., Eichinger, M., Optazaite, D.-E., Puderbach, M., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000530 · Cited by 146
Sverzellati, N., Silva, M., Calareso, G., Galeone, C., Marchianò, A. V., Sestini, S., Sozzi, G., & Pastorino, U. (2016) · European Radiology · doi:10.1007/s00330-016-4228-3 · Cited by 123
Self-citationComputed tomographic characteristics of interval and post screen carcinomas in lung cancer screening
Scholten, E. T., Horeweg, N., de Koning, H. J., Vliegenthart, R., Oudkerk, M., Mali, W. P. T. M., & de Jong, P. A. (2014) · European Radiology · doi:10.1007/s00330-014-3394-4 · Cited by 120
Silva, M., Prokop, M., Jacobs, C., Capretti, G., Sverzellati, N., Ciompi, F., van Ginneken, B., Schaefer‐Prokop, C. M., Galeone, C., Marchianò, A. V., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.013 · Cited by 93
Self-citationLung cancer screening: latest developments and unanswered questions
van der Aalst, C. M., ten Haaf, K., & de Koning, H. J. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30200-4 · Cited by 92
Heleno, B., Siersma, V., & Brodersen, J. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.3056 · Cited by 86
Screening for lung cancer using low dose computed tomography
Tammemägi, M. C., & Lam, S. C. (2014) · BMJ · doi:10.1136/bmj.g2253 · Cited by 82
Biennial lung cancer screening in Canada with smoking cessation—outcomes and cost-effectiveness
Goffin, J. R., Flanagan, W. M., Miller, A. B., Fitzgerald, N. R., Memon, S., Wolfson, M. C., & Evans, W. K. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.09.013 · Cited by 67
Lung cancer risk to personalise annual and biennial follow-up computed tomography screening
Schreuder, A., Schaefer‐Prokop, C. M., Scholten, E. T., Jacobs, C., Prokop, M., & van Ginneken, B. (2018) · Thorax · doi:10.1136/thoraxjnl-2017-211107 · Cited by 46
Cited by
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Cancer Progress and Priorities: Lung Cancer
Schabath, M. B., & Cote, M. L. (2019) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-0221 · Cited by 1,160
Metadata
- Authors
- Pastorino, U., Silva, M., Sestini, S., Sabia, F., Boeri, M., Cantarutti, A., Sverzellati, N., Sozzi, G., Corrao, G., & Marchianò, A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 30
- Issue
- 7
- Pages
- 1162-1169
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2928271642
- Cited by
- 523
- References
- 24
- FWCI
- 44.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.